GlassScriptPhysician profile
Adam Korus
NPI 1801259882
$3,234.20
in general payments reported to CMS, 2019-2025
17 companies · $1,732 in 2025
The $1,732 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $331 · 2024: $1,171 · 2025: $1,732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,234.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,326.32 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $858.15 | 2023-2025 | Airsupra, Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $254.77 | 2024-2025 | Dupixent |
| Verona Pharma, INC. | $183.76 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.08 | 2024-2025 | Ofev, Jascayd |
| Takeda Pharmaceuticals U.S.A., INC. | $89.50 | 2023-2025 | Glassia |
| Electromed, INC. | $79.93 | 2024-2025 | Smartvest |
| Viatris Specialty LLC | $76.38 | 2025 | Yupelri |
| Baxter Healthcare | $64.73 | 2025 | Hillrom - Monarch Airway Clearance System |
| Actelion Pharmaceuticals US, INC. | $48.36 | 2025 | Uptravi, Opsumit |
| Philips North America LLC | $35.18 | 2023-2024 | (Ak6) Vest Therapy |
| Insmed, INC. | $21.39 | 2024 | Arikayce |
| Ambu INC. | $21.29 | 2025 | |
| Merck Sharp & Dohme LLC | $19.58 | 2025 | Zerbaxa |
| Inogen, INC. | $18.66 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $17.01 | 2023 | Lumryz |
| Mylan Specialty L.P. | $13.11 | 2023 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Korus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.